Alunbrig
NICE authorises Takeda’s Alunbrig for ALK-positive advanced non-small cell lung cancer
December 10, 2020Sales and Marketing ALK-positive advanced non-small cell lung cancer, Alunbrig, NICE, Takeda
NICE has published its final appraisal of Takeda’s Alunbrig (brigatinib), recommending the therapy for the treatment of ALK-positive advanced non-small …
Takeda’s Alunbrig outclasses Xalkori to secure EU approval in ALK+ advanced non-small cell lung cancer
April 7, 2020Manufacturing and Production, Sales and Marketing Alunbrig, Europe, Takeda, pharma
The European Commission has ruled to expand the current approved indication of Takeda’s Alunbrig (brigatinib), authorising the drug as a …
European approval for Takeda’s Alunbrig in ALK+ advanced non-small cell lung cancer
November 27, 2018Research and Development, Sales and Marketing Alunbrig, Cancer, Takeda, lung cancer, pharma
Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive …
Takeda’s lung cancer treatment Alunbrig proves successful in Phase III trial
September 26, 2018Research and Development Alunbrig, R&D, Takeda, phase III, research
Japanese pharma firm Takeda have announced that lung cancer treatment Alunbrig has proven successful in reducing the risk of disease …
Takeda’s Alunbrig topples Pfizer’s Xalkori in ALK-positive lung cancer
July 27, 2018Medical Communications, Research and Development Alunbrig, Cancer, NSCLC, Pfizer, Takeda, Xalkori, lung cancer, pharma
Takeda has unveiled new Phase 3 data showing that its tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) not only met its …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
